TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A...

Selecta Biosciences Announces Upcoming Clinical Presentations WATERTOWN, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...